Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2021-11-01

Clinical Trial Update: Trial of Sirolimus for Cognitive Impairment in Sturge-Weber Syndrome [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/3 clinical trial evaluated sirolimus for cognitive impairment in Sturge-Weber syndrome; the study has been completed with results posted in 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Sirolimus (Sirolimus)

Snippet

Sponsor: Anne Comi, MD | Conditions: Sturge-Weber Syndrome | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2021-11-01